📄 Paper V · Biology track

Field Theory of Pathological Bifurcations

Multi-scale phenomenological framework applying TSTU formalism (scalar field, effective mass, criticality) to pathological transitions in biology. Prediction S1 empirically corroborated on NHANES (n=3,138) and calibrated via gold-standard CGM simulation.

Published December 2025 · 📄 Paper V (DOI) · 📊 Addendum B (DOI) · ORCID

Headline result

Elevated glucose variability (CV ≥ 30%) is associated with increased prediabetes risk across 3 independent datasets. Prediction S1 — derived from TSTU bifurcation theory — survives progressively stricter measurement constraints: RR=1.50 (synthetic) → RR=2.36 (NHANES real-world) → RR=1.68 (CGM gold-standard). The observed gradient is consistent with the longitudinal literature (HR ~1.5–2.0).

Theoretical framework

Paper V extends the TSTU framework to biology via a formal analogy: a biological system approaching a pathological transition behaves like a scalar field approaching a critical point. Near the threshold, the effective mass eff tends to zero, producing two observable signatures: critical slowing down (slow recovery from perturbation) and variance amplification (fluctuations grow). The S1 glucose-variability prediction follows directly from this second mechanism.

Three scales, three distinct mathematical frameworks

Addendum A (Dec. 2025) clarifies a critical point: Paper V uses three distinct mathematical frameworks across biological scales. They are not interchangeable and each has its own characteristic timescale.

Scale Model Variables Timescale
Tissue (§3) Klein-Gordon PDE
∂²Φ/∂t² + Γ∂Φ/∂t − c²∇²Φ + V'(Φ) = J
Scalar field Φ (proliferation) Hours–days (fast)
Neural (§4) ODEs E-I-S-N
dE/dt, dI/dt, dS/dt, dN/dt
Excitation, inhibition, sleep, neuro-inflammation 10–30 days (slow)
Systemic (§5) Kuramoto multi-organes
dθᵢ/dt = ωᵢ + ΣKᵢⱼ sin(θⱼ−θᵢ)
Organ phases (liver, heart, ...) Circadian period (24 h)
⚠️ Addendum A correction: Paper V originally claimed τbif ≈ 15 days for the tissue-scale model. 2D simulations with published parameters actually yield τbif ≈ 3 days. The ultra-early clinical detection window therefore narrows from « 2–5 days » to « 6–24 hours ». This correction strengthens the case for continuous tissue monitoring.

Prediction S1 — Glucose variability → diabetes

S1 statement: a glucose coefficient of variation CV ≥ 30% is associated with increased risk of progression to diabetes. Three complementary datasets test this prediction.

Three-validation results

Level 1 — Synthetic
Synthetic cohort
RR = 1.50
95% CI [1.06, 2.31]
n=1,000 · AUC=0.65
Level 2 — Real-world
NHANES 2017–2020
RR = 2.36
95% CI [2.09, 2.65]
n=3,138 · AUC=0.945 · p<0.0001
Level 3 — Gold-standard
CGM simulation (14 d)
RR = 1.68
95% CI [1.55, 1.80]
n=1,000 · AUC=0.739

The observed gradient (synthetic 1.50 → NHANES 2.36 → CGM 1.68) is consistent with two expected mechanisms: (1) cross-sectional confounding inflates associations in NHANES, (2) gold-standard CGM measurement provides stricter calibration. All three results point in the same direction and survive label permutation (null AUC ≈ 0.5).

The independent role of variability

Under gold-standard CGM measurement, logistic regression assigns variability (CV) a standardized coefficient of +1.07, versus +0.41 for mean glucose and −0.09 for time-above-range (TAR). Variability is therefore the dominant predictor, surpassing mean glucose. This is consistent with the theoretical framework: dynamic destabilization precedes mean shift — exactly as predicted by variance amplification near a bifurcation.

Honest limitations:
  • NHANES is cross-sectional — no direct causality. Prediabetes is a prevalent condition, not an incident event.
  • NHANES CV is a proxy (HbA1c–fasting discrepancy, r ≈ 0.3–0.5 with true CGM CV).
  • The CGM cohort is simulated, not empirical. It validates the analysis methodology, not the effect itself.
  • Longitudinal validation required (UK Biobank, ARIC) to move from association to causality.

Implications, conditional on longitudinal validation

The items below are potential research directions that become real only after strict longitudinal validation. No product, no patent, no promise — only possible trajectories.

📱 Integration into clinical CGM

CV ≥ 30% scoring can be integrated as an early-warning flag in existing continuous glucose monitors. Light computation, on-device executable, complementary to current metrics (TIR, GMI).

Dexcom · Abbott · Medtronic · OpenAPS

🔬 UK Biobank longitudinal study

UK Biobank has ~2,500 participants with 14-day CGM monitoring. Direct test: baseline CV → incident diabetes at 5–10 years, Cox proportional hazards.

UK Biobank · ARIC · Framingham · Tidepool

⏱️ Ultra-early elastography (tissue scale)

Addendum A narrows the detection window to 6–24 hours (vs 2–5 days). If verified, daily imaging could detect tissue bifurcations (oncology, hepatic fibrosis) much earlier than current protocols.

Medical imaging · Oncology · Hepatology

🧠 Advanced markers (critical slowing down)

Beyond CV, indicators like lag-1 autocorrelation, variance and skewness can capture critical slowing down. A composite score may improve the current AUC (0.74).

Research · Bioinformatics

Roadmap

  1. Priority 1 — Longitudinal validation (UK Biobank, Framingham, ARIC). Cox on incident-diabetes events at 5–10 years. Expected HR: 1.5–2.0 if causal.
  2. Priority 2 — Real CGM (UK Biobank CGM pilot, n ≈ 2,500). Direct CV measurement, no proxy. Test if RR ≈ 1.6–1.8 confirmed.
  3. Priority 3 — Timescale (high-resolution CGM). Hourly/daily CV preceding diagnosis. Test the 6–24 h window specific to S1.
  4. Priority 4 — Early-warning indicators. Autocorrelation, variance, skewness alongside CV — composite score, target AUC > 0.80.

Collaborate on Paper V

Working on diabetes, CGM, biological systems dynamics, or early detection? Predictions are ready for independent testing, code is public under MIT license.